UPDATE: BMO Capital Markets Increases Target to $16 on Nuvasive

BMO Capital Markets reiterates its perform rating on Nuvasive

and raises its price target to $16 (previously $14) as a worst-case scenario on injunction case appears to be unlikely for now. developments. BMO Capital Markets comments, "Intraday, trading in shares of NUVA were halted when a Bloomberg article highlighted that a Judge had tentatively denied Medtronic's request for a permanent injunction that would have barred NUVA from selling infringing spinal surgery devices. The final judgment regarding the injunction request, along with additional issues including royalty amounts, is expected to be delivered by the end of the 1Q12 or early 2Q12." NUVA closed at $16.25 a share on Wednesday.